Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|23|3795-3811

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.23, 2014-05, pp. : 3795-3811

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Agomelatine for the treatment of major depressive disorder

By Carney Regina M   Shelton Richard C  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 15, 2011-10 ,pp. : 2411-2419

Informa Healthcare

Access to resources Recommend Favorite

cGMP Signaling, Phosphodiesterases and Major Depressive Disorder

By  

Current Neuropharmacology, Vol. 9, Iss. 4, 2011-12 ,pp. : 715-727

Bentham Science Publishers

Access to resources Recommend Favorite

Escitalopram: In the Treatment of Major Depressive Disorder in Adolescent Patients

By Yang Lily P.H.   Scott Lesley J.  

Pediatric Drugs, Vol. 12, Iss. 3, 2010-06 ,pp. : 155-163

Adis International

Access to resources Recommend Favorite

Selegiline Transdermal System: In the Treatment of Major Depressive Disorder

By Frampton James E.   Plosker Greg L.  

Drugs, Vol. 67, Iss. 2, 2007-01 ,pp. : 257-265

Adis International

Access to resources Recommend Favorite

Escitalopram for the treatment of major depressive disorder in youth

By Ahn Joon-Ho   Patkar Ashwin A  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 14, 2011-10 ,pp. : 2235-2244

Informa Healthcare

Access to resources Recommend Favorite